Ligand Pharmaceuticals Incorporated (LGND) Stock Grade

About Ligand Pharmaceuticals Incorporated's fundamentals

Ligand Pharmaceuticals is a $3.7 billion biopharmaceutical company experiencing strong revenue expansion, with year-over-year growth of 60.4% demonstrating significant business momentum. The company maintains an impressive net margin of 46.4%, indicating strong profitability relative to its revenue base, though it does not currently pay a dividend. Trading at a P/E ratio of 29.4, the company's valuation reflects expectations of future earnings growth, while its return on equity of 12.2% shows moderate efficiency in generating profits from shareholder capital.